Escalon(R) Reports First Quarter Fiscal 20... (sare based on the Company's current expe...)

Escalon(R) Reports First Quarter Fiscal 2009 Results

Date:11/13/2008

s are based on the Company's current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether the Company is able to:
-- implement its growth and marketing strategies, improve upon the

operations of the Company business units, including the ability to make

acquisitions and the integration of any acquisitions it may undertake,

if any, of which there can be no assurance,

-- implement cost reductions,

-- generate cash,

-- identify, finance and enter into business relationships and

acquisitions

-- new product development, commercialization, manufacturing and market

acceptance of new products,.

Other factors include uncertainties and risks related to:

-- marketing acceptance of existing products in new markets,

-- research and development activities, including failure to demonstrate

clinical efficacy,

-- delays by regulatory authorities, scientific and technical advances by

the Company or third parties,

-- introduction of competitive products,

-- ability to reduce staffing and other costs and retain benefit of prior

reductions

-- third party reimbursement and physician training, and

-- general economic conditions.

Further information about these and other relevant risks and uncertainties may be found in the Company's report on Form 10-K for year ended June 30, 2008, and its other filings with the Securities and Exchange Commission, all of which are available from the Securities and Exchange Commission as well as other sources.

-Financial Tables Follow-

ESCALON MEDICAL CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

For the Three Months Ended September 30, 2008 2007

Net revenues:

Produ
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine news :

1. Escalon(R) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetric Analyzer
2. Escalon(R) Enhances Position Within IVD Reagent Market with Strategic Acquisition of JAS Diagnostics
3. Escalon(R) Announces China Registration for Sonomed PacScan(R) and E/Z-Scan(R) Series of A-scan, Pachymeter and B-Scan Systems
4. Escalon(R) Announces Executive Promotions
5. Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System
6. Escalon(R) Reports First Quarter Fiscal 2008 Results
7. Escalon(R) Reports Financial Results for 2007 Fiscal Year
8. PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer
9. PA Health Department Reports Southeast Regions First Lab-Confirmed Influenza Case of the Season
10. CDC Reports Drop in Adult Smoking, But Death Toll and Health Costs Are Still Growing; Congress, States Should Implement Proven Solutions
11. Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results

Post Your Comments:

Escalon(R) Reports First Quarter Fiscal 20...(sare based on the Company's current expe...),Health